$662 Million is the total value of First Light Asset Management, LLC's 71 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $61,852,000 | +43.1% | 3,719,291 | +18.4% | 9.35% | +55.8% |
| OMCL | Buy | OMNICELL INC | $32,936,000 | +15.5% | 455,737 | +37.5% | 4.98% | +25.8% |
| KRMD | Buy | REPRO MED SYSTEMS INC | $28,361,000 | +43.0% | 7,180,017 | +4.3% | 4.29% | +55.7% |
| HALO | Buy | HALOZYME THERAPEUTICS INC | $26,099,000 | +42.3% | 1,682,745 | +57.6% | 3.94% | +54.9% |
| INSM | New | INSMED INC | $22,839,000 | – | 1,294,743 | +100.0% | 3.45% | – |
| SPNE | Buy | SEASPINE HOLDINGS CORP | $22,620,000 | -5.2% | 1,852,556 | +2.9% | 3.42% | +3.2% |
| XENT | Buy | INTERSECT ENT INC | $20,686,000 | +35.9% | 1,216,122 | +81.8% | 3.13% | +47.9% |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $20,493,000 | – | 764,096 | +100.0% | 3.10% | – |
| IMMU | Buy | IMMUNOMEDICS INC | $16,582,000 | -2.3% | 1,250,536 | +2.2% | 2.51% | +6.4% |
| AMRN | New | AMARIN CORPORATION | $13,930,000 | – | 918,846 | +100.0% | 2.11% | – |
| ELGXQ | Buy | ENDOLOGIX INC | $11,292,000 | -36.7% | 2,844,317 | +15.5% | 1.71% | -31.0% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $10,771,000 | -12.9% | 332,442 | +34.1% | 1.63% | -5.2% |
| TRHC | New | TABULA RASA HEALTHCARE INC | $10,732,000 | – | 195,347 | +100.0% | 1.62% | – |
| VAPO | Buy | VAPOTHERM INC | $9,695,000 | -15.2% | 1,023,734 | +106.0% | 1.47% | -7.6% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $8,735,000 | +233.3% | 190,838 | +326.9% | 1.32% | +262.6% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $6,979,000 | +16.3% | 103,552 | +47.8% | 1.06% | +26.7% |
| FIXX | New | HOMOLOGY MEDICINES INC. | $2,578,000 | – | 142,449 | +100.0% | 0.39% | – |
| HCAT | New | HEALTH CATALYST INC | $351,000 | – | 11,100 | +100.0% | 0.05% | – |
| TXG | New | 10X GENOMICS INC CLASS A | $252,000 | – | 5,000 | +100.0% | 0.04% | – |
| SNN | New | SMITH & NEPHEW PLC SPONSORED ADR | $215,000 | – | 4,472 | +100.0% | 0.03% | – |
| DYNT | Buy | DYNATRONICS CORP | $122,000 | -37.1% | 121,267 | +3.1% | 0.02% | -33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ATRICURE INC | 40 | Q3 2023 | 9.7% |
| NEOGENOMICS INC | 40 | Q3 2023 | 10.6% |
| SANOFI-SYNTHELABO | 40 | Q3 2023 | 1.9% |
| JOHNSON & JOHNSON | 40 | Q3 2023 | 0.3% |
| PFIZER INC | 39 | Q2 2023 | 0.9% |
| BIOMARIN PHARMACEUTICAL INC | 36 | Q3 2023 | 1.6% |
| OMNICELL INC | 33 | Q3 2023 | 7.7% |
| QUIDEL CORP | 33 | Q4 2021 | 3.7% |
| NOVARTIS AG-SPONSORED ADR | 33 | Q3 2023 | 0.4% |
| MODEL N INC | 30 | Q3 2023 | 9.0% |
View First Light Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| REATA PHARMACEUTICALS INC | May 15, 2023 | 1,290,193 | 3.9% |
| Axogen, Inc. | February 03, 2023 | 1,942,270 | 4.6% |
| MODEL N, INC. | February 03, 2023 | 1,845,134 | 4.9% |
| MEI Pharma, Inc.Sold out | May 31, 2022 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | March 01, 2022 | 1,805,038 | 3.9% |
| Intersect ENT, Inc. | February 14, 2022 | 1,375,210 | 4.1% |
| SeaSpine Holdings Corp | February 14, 2022 | 6,847,707 | 18.8% |
| Oxford Immunotec Global PLCSold out | February 10, 2021 | 0 | 0.0% |
| ENDOLOGIX INC /DE/ | February 14, 2020 | 816,236 | 4.6% |
| Nuvectra CorpSold out | February 14, 2020 | 0 | 0.0% |
View First Light Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-09 |
| 4 | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
View First Light Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.